Integriculture raises Series B from 7 backers to scale cell agriculture
What's the deal? Tokyo-based Integriculture has closed a Series B round backed by seven investors, the company announced in July 2026. The startup develops "cell agriculture" — growing small samples of cells from living organisms to produce cosmetics, cultured foods, and materials.
Who's backing it? The round drew Hiroshima Incubation & Capital, Hiroshima Venture CapitalDealroom has a profile for this one. Try Dealroom →, Daiwa Can CompanyDealroom has a profile for this one. Try Dealroom →, Hakuhodo DY VenturesDealroom has a profile for this one. Try Dealroom →, Yamanashi Chugin Management ConsultingDealroom has a profile for this one. Try Dealroom →, Hamano ProductsDealroom has a profile for this one. Try Dealroom →, and Leave a Nest CapitalDealroom has a profile for this one. Try Dealroom →. The mix spans packaging, manufacturing, marketing, and regional finance.
What's the endgame? Integriculture wants to turn cell culture into shared industrial infrastructure, not just cultured meat. Its core technology, the CulNet® System, cuts culturing costs by avoiding growth factors such as serum, which the company frames as a barrier to mass production.
Where's the money going? Integriculture will accelerate cosmetics product development for early revenue, expand a nationwide implementation network with regional finance and corporate partners, build out sales to win business-to-business customers, and strengthen in-house research.
Why now? Chief executive officer Yuki Hanyu said cell agriculture is "at the coming inflection point," with cosmetics already reaching general distribution in Japan and rulemaking for cultured foods advancing. Chief technology officer Ikko Kawashima likened the goal to an electricity grid: the change came not from generation technology, but from infrastructure "anyone could use."
What could go wrong? Cell agriculture remains capital-intensive and unproven at scale, and Hanyu noted that overseas players face "ups and downs" as focus shifts from technical to commercial validation. Turning lab technology into commodity infrastructure — the company's stated aim — is a long road with regulatory and cost hurdles.
The signal: The round reflects a shift in cell agriculture from technical proof to business proof, with strategic backers across the supply chain betting on Japan building a homegrown, globally minded industry. By tying regional resources to production — from sake breweries to cosmetics factories — Integriculture is positioning itself as infrastructure for a domestic cell-agriculture industry.
Read more: PR TIMES
